| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
|
08.05.2025 08:00:02
|
Novonesis delivered a strong Q1 with 11% organic growth and confirms full-year outlook
COPENHAGEN, Denmark – May 8, 2025. The global leader in biosolutions, Novonesis, had a strong start to its financial year with organic sales growth of 11% and an adjusted EBITDA margin of 38.3%. The company maintains the full-year outlook.
The sales growth was broad-based across both regions and industries. Emerging markets grew by 15% organically, and developed markets increased by 9%. Across all sales areas, the company delivered double-digit growth in the quarter.
Ester Baiget, President & CEO, says:
"We started the year with strong sales growth and earnings. This is a testament to our innovative solutions, resilient global business model, and our ability to continue to meet the increasing demand for biosolutions in an ever-changing world.”
"Emerging markets were a key growth driver, and all our four sales areas grew by double digits. We’re pleased with our progress, and we maintain our full-year financial outlook.”
"Overall, our Q1 performance underscores the value of our solutions in helping customers do more with less—enabling higher yields, improved throughput, enhanced performance, and greater benefits. And it shows that growth and planet stewardship can be two sides of the same coin.”
During the first three months of the financial year, Novonesis launched six innovations including an advanced protease portfolio for swift and efficient stain removal.
Divisional sales performance organic
In the first three months of the financial year, Food & Health Biosolutions grew by 12%, while Planetary Health Biosolutions grew by 11%.
In Food & Health Biosolutions, Food & Beverages grew by 11% with double-digit growth across most categories. In Human Health, organic sales growth was 13% driven by a strong development in Dietary Supplements.
In Planetary Health Biosolutions, Household Care grew by 12%. The strong performance was driven by increased penetration and innovation. Agriculture, Energy & Tech grew by 10% driven by double-digit growth in Energy and Tech.
Regional performance organic
For the first quarter, emerging markets grew by 15% driven by all sales areas. Developed markets grew by 9%, driven by innovation.
For Q1 2025, organic growth rates by geography were 14% in Europe, Middle East & Africa, 7% in North America, 9% in Asia Pacific, and 18% in Latin America.
Outlook for 2025
The 2025 outlook is maintained at 5-8% organic sales growth (6-9% excluding the exit from certain countries) and an adjusted EBITDA margin between 37-38% despite current currency headwinds.
The 2025 outlook is based on current levels of global trade tariffs. Our strong global setup, including flexible regional production capabilities, creates a diversified and resilient business. Additionally, we have confidence in passing on incremental cost driven by tariffs. As a result, we expect no or only marginal net impact from tariffs.
Financial calendar 2025 / 2026
- August 21, 2025: H1 2025 financial results
- November 6, 2025: Q3 2025 financial results
- February 25, 2026: Full-year financial statement 2025
| Media Relations | Investor Relations | ||
| Anne Sophie Scavenius Senior Media Relations Manager Phone: +45 30 77 19 67 anse@novonesis.com | Tobias Cornelius Björklund Head of Investor Relations Phone: +45 30 77 86 82 tobb@novonesis.com |
Attachments
Nachrichten zu Novozymes A-S (B)
|
25.02.25 |
Ausblick: Novozymes A-S (B) mit Zahlen zum abgelaufenen Quartal (finanzen.net) | |
|
11.02.25 |
Novonesis to acquire dsm-firmenich’s share of the Feed Enzyme Alliance (GlobeNewswire) | |
|
11.02.25 |
Erste Schätzungen: Novozymes A-S (B) öffnet die Bücher zum abgelaufenen Quartal (finanzen.net) |
Gold auf $4000? Silber im Defizit! – Invest 2025 mit Jochen Staiger | BX Swiss TV
Gold auf Rekordkurs, Silber im Defizit und Uran vor der Explosion? Im exklusiven Interview auf der Invest 2025 analysiert Jochen Staiger, CEO von Swiss Resource Capital, die Lage an den Rohstoffmärkten. Erfahre, warum gerade jetzt Edelmetalle und Uran extrem spannend sind – und welche Preisziele realistisch sind.
🔍 Themen im Video:
🔹 Goldpreis-Prognose: Warum 4000 USD realistisch sind
🔹 Inflation, Verschuldung & Zentralbanken als Preistreiber
🔹 Silber: Industriemetall im Mangel – Preisexplosion vorprogrammiert?
🔹 7 Jahre Angebotsdefizit – und keine neuen Minen in Sicht
🔹 Uran: Der unterschätzte Rohstoff der Energiewende
🔹 Small Modular Reactors & Reaktorneubauten weltweit
🔹 Preisziel Uran 2025: Verdoppler möglich
🔹 Konkrete Titel-Tipps & Investmentideen
🔹 Warum Rohstoffe langfristig in jedes Portfolio gehören
👉🏽 Jetzt auch auf BXplus anmelden und von exklusiven Inhalten rund um Investment & Trading profitieren!
Inside Trading & Investment
Mini-Futures auf SMI
Aktien in diesem Artikel
| Novozymes A-S (B) | 44.68 | -6.35% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Hoffen auf Entspannung im Ukraine-Konflikt: US-Börsen schliessen tiefer -- SMI letztlich mit Gewinnen -- DAX beendet Handel über 24'000 Punkten -- Gewinne an den Börsen in AsienAm heimischen Aktienmarkt zeigten sich am Dienstag leichte Gewinne. Der DAX übersprang erstmals die 24'000-Punkte-Marke. An der Wall Street präsentierte sich ein schwächerer Handel. In Fernost herrschte positive Handelsstimmung.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |